The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review
- PMID: 36672305
- PMCID: PMC9857064
- DOI: 10.3390/cancers15020355
The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review
Abstract
Background: Recent articles proposed the employment of positron emission tomography/computed tomography (PET/CT) with prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals in clear cell renal cell carcinoma (ccRCC).
Methods: The authors performed a comprehensive literature search of studies on the performance of PET/CT with PSMA-targeting radiopharmaceuticals in ccRCC. Original articles concerning this imaging examination were included in newly diagnosed ccRCC patients and ccRCC patients with disease recurrence.
Results: A total of sixteen papers concerning the diagnostic performance of PSMA-targeted PET/CT in ccRCC (331 patients) were included in this systematic review. The included articles demonstrated an excellent detection rate of PSMA-targeting PET/CT in ccRCC.
Conclusions: PSMA-targeted PET/CT seems promising in detecting ccRCC lesions as well as in discriminating the presence of aggressive phenotypes. Prospective multicentric studies are warranted to strengthen the role of PSMA-targeting PET/CT in ccRCC.
Keywords: PET; PSMA; clear cell renal cell carcinoma; imaging; kidney; nuclear medicine; oncology.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


References
-
- Heng D.Y., Xie W., Regan M.M., Warren M.A., Golshayan A.R., Sahi C., Eigl B.J., Ruether J.D., Cheng T., North S., et al. Prognostic Factors for Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor–Targeted Agents: Results from a Large, Multicenter Study. J. Clin. Oncol. 2009;27:5794–5799. doi: 10.1200/JCO.2008.21.4809. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous